在内镜检查前使用的葡萄糖类受体激动剂与低保留的胃含量有关:多中心横截面分析
Jennifer Phan1, Patrick Chang1, Danny Issa2
1Keck Hospital of USC, Los Angeles, California, USA.
The American journal of gastroenterology
|July 17, 2024
概括
类似葡萄糖类受体激活剂 (GLP1-RAs) 在内镜检查期间显示胃留率较低,主要是在2型糖尿病患者中. 建议采用个性化的方法来进行手术前保持GLP1-RAs,而不是普遍停止治疗.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 麻醉学 麻醉学
背景情况:
- 在内镜检查之前,关于在手术前保持葡萄糖类受体激动剂 (GLP1-RAs) 的指导方针存在矛盾.
- 由于GLP1-RAs的使用越来越多,因此需要澄清它们在手术过程中对胃内容的影响.
研究的目的:
- 评估GLP1-RAs在上部内镜检查期间对胃留的作用.
- 基于遵守美国麻醉师协会 (ASA) 的手术前持有指导的结果进行比较.
主要方法:
- 在815名接受内镜检查的GLP1-RA患者的多中心横截面研究 (2021-2023年).
- 收集的数据包括人口统计,GLP1-RA管理和程序结果.
- 多变量后勤回归分析了与保留的胃内容相关的因素.
主要成果:
- 8.7%的患者保留了胃部的内容,主要是2型糖尿病患者.
- 按ASA指南保持GLP1-RA与较少保留的胃内容 (4.4%对12.7%) 有关.
- 由于胃滞留而导致的输管或手术流产率没有显著差异.
结论:
- 在接受GLP1-RAs的患者内镜检查期间保留的胃内容是罕见的.
- 这些发现支持针对GLP1-RAs的个性化手术前管理策略,考虑患者特定的因素,如血糖控制 (HbA1C).
相关概念视频
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
244
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
244
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180


